Adora Animal Health has filed a notice of an exempt offering of securities to raise $10 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Adora Animal Health is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Adora Animal Health
We are committed to improving the health of animals and humans worldwide with our fundamental understanding of drug manufacturing and pharmaceutical enterprise management. We believe in scientific rigor, innovation and passion as driving forces, merging research, emerging technologies and operational excellence. Adora Life Science (Adora) is a U.S.-based biopharmaceutical company developing and commercializing a portfolio of products for the treatment of joint and muscle pain, oral health and dermatological conditions impacting human and animal health. Working with natural biomolecules, Adora has developed proprietary, validated processes and analytical methods yielding unique formulations as a competitive alternative to non-steroidal analgesics (NSAIDS).
To learn more about Adora Animal Health, visit https://adoralifescience.com/
Adora Animal Health Linkedin Page: https://www.linkedin.com/company/adora-life-science/
Contact:
Thomas Vaughn, President
615-582-1002
https://www.linkedin.com/in/mike-vaughn-07771120/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
